Ibogaine Clinical Trials 2026: The Complete Research Tracker

After decades in the scientific wilderness, ibogaine research is experiencing an unprecedented acceleration. In the past two years, peer-reviewed publications in Nature Medicine and Nature Mental Health have validated what thousands of patients treated in clinical settings outside the US already knew — ibogaine can produce rapid, durable relief from opioid dependence, PTSD, and traumatic brain injury.

This page tracks every significant ibogaine clinical trial worldwide, with NCT numbers, principal investigators, published results, and the regulatory pathway toward potential FDA approval. We update this tracker as new data emerges.

1. Stanford MISTIC Trial — The Breakthrough That Changed Everything

The Stanford MISTIC (Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS) program represents the most significant ibogaine clinical research to date. Led by Dr. Nolan Williams, the study treated 30 Special Operations veterans — a population with notoriously treatment-resistant PTSD and traumatic brain injury (TBI).

Key Results

The January 2024 Nature Medicine publication (DOI) reported:

• WHODAS disability score: 30.2 (baseline, mild-to-moderate disability) → 19.9 (immediately post-treatment) → 5.1 at one month (effectively no disability)
• PTSD: 100% response rate at 1 month; 86% remission
• Depression: 97% response rate at 1 month; 83% remission
• Anxiety: 93% response rate at 1 month; 83% remission
• Suicidal ideation: dropped from 47% of participants at baseline to 7% at one-month follow-up
• Zero serious cardiac adverse events — no bradycardia, tachycardia, clinically meaningful QT prolongation, or hemodynamic instability

Dr. Williams stated: "No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury."

Neural Mechanism Discovery (July 2025)

A follow-up study published in Nature Mental Health in July 2025 used EEG and MRI to identify the brain changes underlying ibogaine's effects:

• Veterans with improved executive function showed increased theta rhythms — brain waves associated with learning, memory, and cognitive flexibility
• Veterans with reduced PTSD symptoms showed decreased cortical complexity — suggesting normalization of hyperactive neural circuits
• After treatment, slower oscillations (theta–alpha) increased in power while higher-frequency activity (beta–gamma) decreased — a pattern consistent with neural "resetting"

Brain Structure Changes (2025)

A third study from the same cohort, published in the Archives of Physical Medicine and Rehabilitation, found significant increases in cortical thickness in 11 brain regions approximately 7 days after ibogaine treatment — changes sustained at 1-month follow-up. The findings suggest ibogaine may reduce accelerated brain aging in veterans with multiple blast-related TBI.

Mystical Experiences and PTSD Outcomes

A separate analysis published in the Journal of Affective Disorders (PMID: 41265656) found that veterans who reported greater intensity of mystical experiences during ibogaine treatment showed significantly larger reductions in PTSD scores — both immediately post-treatment and at one month. This supports the growing evidence that the subjective psychedelic experience itself may be therapeutically relevant.

These findings provide the first neuroimaging evidence of how ibogaine produces its therapeutic effects, strengthening the scientific case for larger trials. For more on how ibogaine affects the heart during treatment, see our cardiac risks deep-dive.

2. Texas $50M IMPACT Consortium — The Largest Government-Funded Ibogaine Program

In December 2025, the State of Texas awarded $50 million to UTHealth Houston and UTMB Health to establish the IMPACT (Ibogaine Multisite Platform for Addiction and CNS Therapeutics) consortium — making it the largest government-funded ibogaine research program in history.

Why Texas?

Texas has been at the forefront of ibogaine advocacy, driven by several converging factors:

• A severe opioid crisis — Texas saw over 5,000 opioid overdose deaths in 2023
• A large veteran population — second only to California, with 1.5 million veterans, many suffering from treatment-resistant PTSD and TBI
• The VALOR Coalition, chaired by Amber Capone (VETS co-founder), which organized a national alliance of veteran organizations to advocate for ibogaine access
• Strong bipartisan support — former Governor Rick Perry co-founded Americans for Ibogaine and called ibogaine research "the focus of my life's work"

Research Scope

The IMPACT consortium will study ibogaine for:

• Opioid use disorder (OUD) — the primary focus, targeting treatment-resistant patients who have failed conventional MAT
• Co-occurring substance use disorders — polysubstance addiction involving opioids plus stimulants, alcohol, or benzodiazepines
• PTSD and traumatic brain injury — building on Stanford's MISTIC findings, with a focus on Texas's veteran population
• Neurological conditions — exploratory research into ibogaine's neurotrophic effects (GDNF upregulation) for broader CNS applications

The program is expected to generate the clinical data necessary to support an FDA New Drug Application (NDA) — potentially the most direct path to legal ibogaine treatment in the United States.

3. DemeRx/atai Life Sciences — Pharmaceutical-Grade Ibogaine (DMX-1002)

DemeRx, a subsidiary of publicly traded atai Life Sciences (NASDAQ: ATAI), is pursuing the most advanced pharmaceutical pathway for ibogaine. Their compound DMX-1002 is pharmaceutical-grade ibogaine hydrochloride, manufactured under GMP conditions for clinical use.

Phase 1 Results (August 2023)

The single-blinded Phase 1 study tested single-ascending doses in 20 healthy volunteers:

• Doses tested: 3 mg/kg, 6 mg/kg, and 9 mg/kg
• Safety: Over 94% of adverse events were mild-to-moderate. No serious adverse events
• Cardiac signal: QTc prolongation at 9 mg/kg approached levels previously seen at 10 mg/kg in published literature — manageable with cardiac monitoring
• Pharmacokinetics: dose-proportional increases in ibogaine and noribogaine plasma levels confirmed

Phase 1/2a — UK Trial

DemeRx received MHRA (UK Medicines and Healthcare products Regulatory Agency) approval to commence a Phase 1/2a study of DMX-1002 for opioid use disorder — the first ibogaine clinical trial for OUD in the United Kingdom. This study will test ibogaine in patients actively dependent on opioids, not just healthy volunteers.

IBX-210 — IV Formulation

atai is also developing IBX-210, a novel intravenous formulation of ibogaine designed for more precise dosing and faster onset. Additional non-clinical studies are planned before a Phase 1b trial launch.

The pharmaceutical development pathway is significant because it establishes the manufacturing, safety, and efficacy data that the FDA requires for approval — data that clinic-based ibogaine treatment has never generated at the rigor level demanded by regulators.

4. ICEERS Spain Trial — First Phase II for Methadone Patients

The ICEERS trial is notable for being the first Phase II clinical trial to study ibogaine specifically in patients on methadone maintenance therapy — a population with unique risks and challenges.

Why Methadone Patients Matter

Methadone-to-ibogaine transitions are among the most dangerous in addiction medicine. Methadone independently prolongs the QT interval, and its extremely long half-life (15–60 hours) means cardiac risk compounds with ibogaine's own hERG channel blockade. Multiple documented ibogaine fatalities involved patients who had not fully cleared methadone from their system.

A controlled clinical trial studying this specific transition — with proper cardiac monitoring, electrolyte management, and standardized taper protocols — could establish the first evidence-based safety guidelines for this high-risk population.

Study Design

Participants are recruited from the hospital's Methadone Maintenance Program, ensuring clinical oversight of the taper process before ibogaine administration. The study measures:

• Primary outcome: Efficacy of ibogaine in facilitating methadone detoxification
• Safety outcomes: Cardiac monitoring (continuous ECG), adverse events, vital signs
• Secondary outcomes: Withdrawal severity scores, craving reduction, follow-up abstinence rates

5. Next-Generation Ibogaine Analogs — Removing the Cardiac Risk

While ibogaine itself is being studied in clinical trials, several companies are developing modified versions designed to keep the therapeutic effects while eliminating the dangerous cardiac risks:

Tabernanthalog (Delix Therapeutics)

Researchers at UC Davis developed tabernanthalog (TBG), a non-hallucinogenic ibogaine analog that promotes neuroplasticity without affecting hERG potassium channels. A December 2020 study in Nature demonstrated that TBG:

• Promoted dendritic growth and neural connectivity comparable to ibogaine
• Reduced alcohol and heroin self-administration in rodent models
• Produced anti-depressant effects without hallucinations
• Showed no cardiac toxicity at therapeutic doses

Delix Therapeutics, the company commercializing TBG, is developing a pipeline of non-hallucinogenic psychedelic analogs targeting addiction, depression, and neurodegeneration.

18-Methoxycoronaridine (18-MC)

18-MC is a synthetic ibogaine derivative developed by Dr. Stanley Glick at Albany Medical College. It selectively targets alpha-3-beta-4 nicotinic receptors — one of ibogaine's key anti-addiction mechanisms — while avoiding serotonin and hERG channel interactions. Preclinical studies showed reduced self-administration of morphine, cocaine, methamphetamine, nicotine, and alcohol in animal models.

Why Analogs Matter

The FDA approval pathway for ibogaine itself faces a fundamental challenge: the drug's cardiac risks require intensive medical monitoring, limiting scalability. A non-cardiotoxic analog could be prescribed more broadly — potentially in outpatient settings — dramatically expanding access. However, no analog has yet replicated ibogaine's full spectrum of effects in humans. The "psychedelic experience itself" may be therapeutically relevant, which non-hallucinogenic analogs inherently sacrifice.

6. Real-World Clinical Data — Beond Health & Ambio Life Sciences

While controlled clinical trials progress through regulatory pathways, two organizations are generating the largest bodies of real-world ibogaine treatment data in the world. Their outcomes — collected under medical supervision with standardized protocols — provide critical evidence that complements the controlled trial pipeline.

Beond Health (Cancún, Mexico)

Beond Health operates the largest dedicated ibogaine treatment facility in the world, treating PTSD, TBI, depression, anxiety, and substance use disorders including opioid, alcohol, stimulant, and ketamine addiction. Their Beond Ibogaine Research and Policy Institute conducts systematic data collection with remote digital monitoring post-treatment.

Their Beond Service program is specifically designed for military veterans and first responders, featuring cutting-edge research-based protocols, family support components, and comprehensive aftercare including a new Austin, Texas location for education, preparation, and integration.

Ambio Life Sciences — Neurodegenerative Conditions

Ambio Life Sciences launched the world's first clinical ibogaine program for neurodegenerative conditions in February 2025, treating patients with Parkinson's disease, multiple sclerosis (MS), essential tremor, stroke, TBI, and ALS. Early results are remarkable:

• A case report published in Frontiers in Immunology (2025) documented significant lesion reduction and neurostructural changes in 2 progressive MS patients
• Patient-reported improvements include relief from eyesight problems, mobility gains, and neuropathic pain reduction
• 30 patients enrolled in the soft-launched program to date
• Ambio co-authored the Stanford 30-veteran TBI analysis and collects real-world data from all consenting participants

A separate MAPS-funded study through Ambio found a 50% opioid abstinence rate at 30 days — consistent with the broader literature while adding real-world evidence from a medically supervised clinical setting.

7. Regulatory & Legislative Landscape

Federal Status

Ibogaine is classified as a Schedule I controlled substance under the US Controlled Substances Act, alongside MDMA, psilocybin, and LSD. This classification means it is considered to have:

• High potential for abuse
• No currently accepted medical use
• Lack of accepted safety for use under medical supervision

However, the FDA grants Investigational New Drug (IND) exemptions for Schedule I research, which is how Stanford, DemeRx, and the Texas IMPACT consortium operate legally. The FDA has shown increasing willingness to authorize psychedelic research — evidenced by breakthrough therapy designations for psilocybin (2018, 2019) and MDMA (2017).

State-Level Developments

• Texas (SB 2308): Authorized $50M for ibogaine clinical trials through the IMPACT consortium. The most significant state-level ibogaine legislation to date.
• Texas (HB 3717): The VALOR Coalition's landmark bill allocating additional public and private funding for ibogaine research focused on veterans with OUD, co-occurring SUD, and neurological conditions.
• Oregon (HB 4110): Passed February 12, 2026, making Oregon the first state in the US to legalize physician-supervised ibogaine treatment. Effective January 1, 2027, HB 4110 authorizes ibogaine for PTSD, major depressive disorder, anxiety disorders, and substance use disorder under licensed physician supervision. Requirements include mandatory pre-treatment EKG, continuous cardiac monitoring, and a minimum of 3 follow-up integration therapy sessions. Bipartisan sponsors include Rep. Alek Skarlatos (R) and Rep. Rob Nosse (D).
• Arizona (HB 2871): Appropriated $5 million over 5 years (FY 2025–2030) for Phase 1–3 ibogaine clinical research trials through the Arizona Biomedical Research Centre (ABRC). Grants are restricted to Arizona-based institutions with neurosurgery programs and proven neuroscience research history. Arizona becomes the second state after Texas to allocate public funds for ibogaine research.
• Kentucky: Introduced legislation in 2024 to fund ibogaine research for its severe opioid crisis.

International Legal Status

Ibogaine is legal or unregulated in most countries outside the US. Clinical treatment is available in Mexico, Canada, Costa Rica, Brazil, New Zealand, and throughout much of Europe and Central America. This has created a "medical tourism" industry that the clinical trial pipeline may eventually replace with domestic access. See our complete legal status guide for country-by-country details.

8. Active Ibogaine Clinical Trials — Comparison Table

9. Veterans Advocacy & Political Momentum

The acceleration of ibogaine research is inseparable from the advocacy of the veteran community — particularly Marcus and Amber Capone and their organization VETS (Veterans Exploring Treatment Solutions).

The Capone Story

Marcus Capone, a former Navy SEAL, suffered from severe PTSD and traumatic brain injury after multiple combat deployments. After conventional treatments failed, he received ibogaine therapy — and experienced what he described as a transformative recovery. His wife Amber, who left a successful real estate career to co-found VETS, has since become the most visible advocate for ibogaine access in the United States.

• Amber Capone chairs the VALOR Coalition, a national alliance of veteran organizations that spearheaded the Texas ibogaine initiative
• Named to Inc.'s 2025 Female Founders 500 list for her work with VETS
• VETS has funded ibogaine treatment for hundreds of veterans through clinical providers outside the US

Celebrity & Public Figure Endorsements

Several high-profile individuals have publicly shared their ibogaine experiences, generating mainstream awareness:

• Jordan Belfort — former Wall Street trader, publicly credited ibogaine with helping him overcome addiction
• Jillian Michaels — fitness expert, discussed ibogaine therapy on major media platforms
• Dr. Mark Hyman — functional medicine physician, advocated for ibogaine research
• Bruce Irons — professional surfer, shared his ibogaine recovery story

While celebrity endorsements do not constitute medical evidence, they have proven effective at drawing political attention and public funding to ibogaine research — a pattern previously seen with psilocybin and MDMA advocacy. For evidence-based information on ibogaine's effectiveness, see our research & evidence page.

10. Frequently Asked Questions

Last updated: March 2, 2026. This tracker is updated as new trial data, regulatory decisions, and publications emerge.